Subscribe to RSS
DOI: 10.1055/s-0030-1262515
© Thieme Medical Publishers
A Patient with Chronic Hepatitis B and Regression of Fibrosis during Treatment
Publication History
Publication Date:
21 July 2010 (online)
![](https://www.thieme-connect.de/media/sld/201003/lookinside/thumbnails/10.1055-s-0030-1262515-1.jpg)
ABSTRACT
We present a patient with HBeAg-negative chronic hepatitis B, in whom significant regression of hepatic fibrosis was achieved after a lengthy antiviral treatment. A liver biopsy specimen obtained at initiation of treatment showed chronic hepatitis B with mild activity (histologic activity index: 7) and marked fibrosis (stage 4, in a scale of 0 to 6). A second biopsy specimen, obtained 10 years later, demonstrated almost complete resolution of necroinflammatory activity and fibrosis. One year after the second biopsy, seroconversion from HBsAg positive to anti-HBs positive status was achieved, and antiviral treatment was discontinued. This case is illustrative of the significant histologic improvement that can be accomplished in chronic hepatitis B when viral activity is suppressed long term. Lengthy antiviral treatment can achieve resorption of excess fibrous tissue, even in patients with marked fibrosis.
KEYWORDS
Chronic hepatitis B - HBsAg seroconversion - regression of fibrosis
REFERENCES
- 1 Ishak K, Baptista A, Bianchi L et al.. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6) 696-699
- 2 Poynard T, McHutchison J, Manns M et al.. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002; 122(5) 1303-1313
- 3 Dienstag J L, Goldin R D, Heathcote E J et al.. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124(1) 105-117
- 4 Czaja A J, Carpenter H A. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004; 40(4) 646-652
- 5 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004; 39(6) 1647-1654
- 6 Falize L, Guillygomarc'h A, Perrin M et al.. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006; 44(2) 472-477
- 7 Chang T T, Gish R G, de Man R BEHoLD AI463022 Study Group et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10) 1001-1010
- 8 Lai C L, Shouval D, Lok A S BEHoLD AI463027 Study Group et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354(10) 1011-1020
- 9 Hadziyannis S J, Tassopoulos N C, Heathcote E J Adefovir Dipivoxil 438 Study Group et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131(6) 1743-1751
- 10 Marcellin P, Heathcote E J, Buti M et al.. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23) 2442-2455
- 11 Schiff E, Simsek H, Lee W M et al.. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008; 103(11) 2776-2783
- 12 Moucari R, Korevaar A, Lada O et al.. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009; 50(6) 1084-1092
- 13 Wanless I R, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000; 124(11) 1599-1607
- 14 Malekzadeh R, Mohamadnejad M, Rakhshani N et al.. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol. 2004; 2(4) 344-347
- 15 Bortolotti F, Guido M, Cadrobbi P et al.. Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis. 2005; 37(12) 964-967
- 16 Serpaggi J, Carnot F, Nalpas B et al.. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006; 37(12) 1519-1526
- 17 Friedman S L. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6) 1655-1669
- 18 Jiao J, Friedman S L, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009; 25(3) 223-229
- 19 Anthony P P, Ishak K G, Nayak N C, Poulsen H E, Scheuer P J, Sobin L H. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ. 1977; 55(4) 521-540
-
20 Wanless I R.
Vascular disorders . In: Burt AD, Portmann BC, Ferrell LD MacSween's Pathology of the Liver. 5th ed. Philadelphia; Churchill Livingstone 2007: 613-648 - 21 Nakashima E, Kage M, Wanless I R. Idiopathic portal hypertension: histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis. Hepatology. 1999; 30 218A
- 22 Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991; 13(3) 372-374
- 23 Bedossa P, Poynard T. The METAVIR Cooperative Study Group . An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996; 24(2) 289-293
- 24 Hytiroglou P, Thung S N, Gerber M A. Histological classification and quantitation of the severity of chronic hepatitis: keep it simple!. Semin Liver Dis. 1995; 15(4) 414-421
- 25 Afdhal N H, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol. 2004; 99(6) 1160-1174
- 26 Sorrell M F, Belongia E A, Costa J et al.. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5, Suppl) S4-S12
- 27 Feld J J, Wong D KH, Heathcote E J. Endpoints of therapy in chronic hepatitis B. Hepatology. 2009; 49(5, Suppl) S96-S102
- 28 Huo T I, Wu J C, Lee P C et al.. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998; 28(1) 231-236
- 29 Chen Y C, Sheen I S, Chu C M, Liaw Y F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002; 123(4) 1084-1089
- 30 Yuen M F, Wong D K, Fung J et al.. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135(4) 1192-1199
- 31 Liaw Y F, Sheen I S, Chen T J, Chu C M, Pao C C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991; 13(4) 627-631
- 32 McMahon B J. The natural history of chronic hepatitis B virus infection. Hepatology. 2009; 49(5, Suppl) S45-S55
- 33 Lampertico P, Del Ninno E, Viganò M et al.. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003; 37(4) 756-763
- 34 Marcellin P, Lau G KK, Bonino F Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351(12) 1206-1217
- 35 Hadziyannis S, Sevastianos V, Rapti I. Outcome of HBeAg-negative chronic hepatitis B 5 years after discontinuation of long term adefovir dipivoxil treatment. J Hepatol. 2009; 50(Suppl 1) S9
Prodromos HytiroglouM.D.
Department of Pathology, Aristotle University Medical School
540 06 Thessaloniki, Greece
Email: phitir@med.auth.gr